Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. GlobalData estimates that global annual sales for datopotamab deruxtecan in the NSCLC setting will exceed $500m in 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

Pharmaceutical Technology

MARCH 30, 2023

The drug is approved in several indications, including advanced melanoma, metastatic non-small cell lung cancer (NSCLC), and relapsed classical Hodgkin lymphoma (cHL). As per GlobalData’s consensus forecasts, the drug is estimated to yield global sales of $34.79 billion in 2028. billion in 2028.

Food and Drug Administration 52

Food and Drug Administration FDA Sales Food 52

Pharmaceutical Technology

JULY 12, 2022

The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

Leads 52

Leads Food and Drug Administration Marketing Sales 52

Medico Reach

OCTOBER 17, 2022

million by 2028. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. Now, the demand for such equipment is on track to grow exponentially. Development Of New Biotech Coating In Orthopedic Medical Devices.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

pharmaphorum

SEPTEMBER 13, 2022

Just over a decade after it was developed by biochemist Nicholas Lyndon, Imatinib received US Food and Drug Administration (FDA) approval in 2001. Since then, it has transformed the treatment of chronic myeloid leukaemia and non-Hodgkin’s lymphoma. 2002 – Emergence of CAR-T therapy.

Food and Drug Administration 98

Food and Drug Administration Patients Engineering Physicians 98

Medico Reach

OCTOBER 17, 2022

million by 2028. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. Now, the demand for such equipment is on track to grow exponentially. Development Of New Biotech Coating In Orthopedic Medical Devices.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

Pharmaceutical Technology

JUNE 16, 2023

In 2021, as part of the same Keynote-811 trial, the US Food and Drug Administration (FDA) granted accelerated approval to Keytruda for treating locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, in combination with trastuzumab and chemotherapy containing fluoropyrimidin and platinum.

Food and Drug Administration 52

Food and Drug Administration FDA Prospecting Food 52

World of DTC Marketing

APRIL 7, 2022

By 2028, these costs are expected to climb to $6.2 Launch prices of new cancer drugs in the U.S. Food and Drug Administration (FDA). billion estimated cumulative spending on the new oral targeted cancer drugs by the end of 2018. THREAT 3: RISING HEALTHCARE COSTS. A study reported that U.S. billion in 1970.

Healthcare 215

Healthcare Healthcare Food and Drug Administration Government 215